The share price of NanoVibronix, Inc. (NASDAQ: NAOV) increased significantly during pre-market trading, going up 79.82% to $3.92 as of the last check. The notable increase follows the publication of a successful independent study evaluating the company’s primary medical product, UroShield, by the Australian and New Zealand Continence Journal.
An independent Validates UroShield’s Effectiveness
The study highlights the device’s efficacy in reducing catheter-associated urinary tract infections (CAUTIs) and its potential for widespread clinical use among patients with indwelling urinary catheters (IUCs). UroShield customers showed encouraging outcomes from the independent health service research showing that Catheter blockages reduced by 70% while Catheter changes decreased by 52.3%.
The positive impact of the device on patient care is further supported by the fact that clinicians saw less catheter-related interventions and more patient comfort. The study also discovered that UroShield decreased nursing effort and produced measurable cost savings for medical professionals.
Better Patient Results and Cost Effectiveness
The effectiveness of UroShield in a New Zealand District Nursing Service was described in depth in the published study, which also highlighted how it improves the quality of life for patients with IUCs. UroShield dramatically decreased catheter-associated infections and obstructions, resulting in fewer medical interventions and improved patient comfort, according to the Quality Improvement initiative.
Furthermore, during a five-month period, the final cost analysis showed a 63.5% drop in resource consumption, mostly as a result of fewer medical interventions and emergency call-outs.
Devices of the Future in Development
Along with the encouraging trial findings, NanoVibronix recently reported that the design process for its next PainShield and UroShield devices was finished. In December 2024, a third-party contractor completed the creation of the prototype with an emphasis on lowering assembly costs, minimizing risk factors, and improving user ease.
These advancements show NanoVibronix’s continuous efforts towards innovation in medical technology and supporting its prospects for further market expansion and acceptance. With these developments, NAOV is securing its position in the healthcare sector by offering innovative solutions to improve patient care and operational efficacy.